On February 14, 2023, Jonathan Zung, Ph.D., the Chief Development Officer of Evelo Biosciences, Inc., was informed that his position was being eliminated in connection with the Company's previously announced cost savings initiatives. Dr. Zung is expected to serve in his position through March 3, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | -50.00% | -99.83% | -99.84% |
05-02 | North American Morning Briefing : Stock Futures -2- | DJ |
04-25 | North American Morning Briefing : More Tech -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
-99.84% | 1.9K | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- EVLO Stock
- News Evelo Biosciences, Inc.
- Evelo Biosciences, Inc. Eliminates Position of Jonathan Zung, Chief Development Officer